BioSpace News Archive

AlzeCure Pharma AB announced that the company is participating at the leading Norwegian bank DNB’s Nordic-American Healthcare Conference in New York on December 6 at 2:30 pm EST, where CEO Martin Jönsson will present and answer questions about the latest developments and the company’s plans going forward.

TOLREMO therapeutics AG announced that the first patient has been dosed in its first-in-human clinical trial evaluating the safety and tolerability, pharmacokinetics, and pharmacodynamics of its lead candidate, TT125-802, in patients across a range of solid tumor indications.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that management will present at two upcoming investor conferences.

Novavax, Inc. announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine has been granted Emergency Use Listing by the World Health Organization for active immunization to prevent COVID-19 in individuals aged 12 and older.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data across a range of assets and blood cancers at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 9-12 in San Diego, California.

Centogene N.V. announced that it has completed the transaction to form a new joint venture with Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund.

Zomedica Corp. announced that the management team will be attending Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference at Florida Atlantic University’s Executive Education Complex in Boca Raton, Florida on December 5, 2023.

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Single-Ascending Dose part of the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s broad-spectrum antiviral drug, was completed successfully.

Merck, known as MSD outside of the United States and Canada, announced results from STRIDE-3, a Phase 3 trial evaluating V116, the company’s investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) today announced that it will host a webcast on Tuesday, December 12, 2023 at 4:30 PM ET to present new Phase 1 dose escalation data for relapsed refractory multiple myeloma from the ongoing Phase 1/2 clinical trial of CFT7455, a MonoDAC™ degrader of IKZF1/3, for the potential treatment of relapsed/refractory multiple myeloma and relapsed/refractory non-Hodgkin’s lymphoma.